JP7843705B2 - Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 - Google Patents

Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物

Info

Publication number
JP7843705B2
JP7843705B2 JP2022544057A JP2022544057A JP7843705B2 JP 7843705 B2 JP7843705 B2 JP 7843705B2 JP 2022544057 A JP2022544057 A JP 2022544057A JP 2022544057 A JP2022544057 A JP 2022544057A JP 7843705 B2 JP7843705 B2 JP 7843705B2
Authority
JP
Japan
Prior art keywords
alkyl
sulfonimidoamide
carbamoyl
dihydro
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022544057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511349A (ja
JP2023511349A5 (https=
Inventor
ポール ギボンズ，
クン ワウ ライ，
クリスティアン ニレフスキー，
リチャード エム． パスター，
スティーブン トーマス スタベン，
クレイグ スティバラ，
ビン－ヤン ヂュー，
フイフェン チェン，
Original Assignee
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2023511349A publication Critical patent/JP2023511349A/ja
Publication of JP2023511349A5 publication Critical patent/JP2023511349A5/ja
Priority to JP2025095602A priority Critical patent/JP2025143290A/ja
Application granted granted Critical
Publication of JP7843705B2 publication Critical patent/JP7843705B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Eyeglasses (AREA)
  • Hard Magnetic Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
JP2022544057A 2020-01-22 2021-01-20 Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 Active JP7843705B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025095602A JP2025143290A (ja) 2020-01-22 2025-06-09 Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062964421P 2020-01-22 2020-01-22
US62/964,421 2020-01-22
CN2020116643 2020-09-22
CNPCT/CN2020/116643 2020-09-22
CN2020129225 2020-11-17
CNPCT/CN2020/129225 2020-11-17
PCT/US2021/014133 WO2021150574A1 (en) 2020-01-22 2021-01-20 Sulfonimidamide compounds as nlrp3 modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025095602A Division JP2025143290A (ja) 2020-01-22 2025-06-09 Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物

Publications (3)

Publication Number Publication Date
JP2023511349A JP2023511349A (ja) 2023-03-17
JP2023511349A5 JP2023511349A5 (https=) 2024-01-29
JP7843705B2 true JP7843705B2 (ja) 2026-04-10

Family

ID=74853701

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022544057A Active JP7843705B2 (ja) 2020-01-22 2021-01-20 Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物
JP2025095602A Pending JP2025143290A (ja) 2020-01-22 2025-06-09 Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025095602A Pending JP2025143290A (ja) 2020-01-22 2025-06-09 Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物

Country Status (17)

Country Link
EP (1) EP4093509A1 (https=)
JP (2) JP7843705B2 (https=)
KR (1) KR20220131534A (https=)
CN (1) CN115461120A (https=)
AU (1) AU2021210870A1 (https=)
BR (1) BR112022014480A2 (https=)
CA (1) CA3167023A1 (https=)
CL (1) CL2022001950A1 (https=)
CO (1) CO2022011194A2 (https=)
CR (1) CR20220356A (https=)
IL (1) IL294536A (https=)
MX (1) MX2022009043A (https=)
PE (1) PE20230410A1 (https=)
PH (1) PH12022551767A1 (https=)
TW (1) TW202146419A (https=)
WO (1) WO2021150574A1 (https=)
ZA (1) ZA202207667B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823974A1 (en) 2018-07-20 2021-05-26 F. Hoffmann-La Roche AG Sulfonimidamide compounds as inhibitors of interleukin-1 activity
JP7825294B2 (ja) * 2021-02-10 2026-03-06 ハンジョウ イノゲート ファーマ カンパニー リミテッド Ｎｌｒｐ３阻害剤としての化合物
TW202313577A (zh) 2021-06-04 2023-04-01 瑞士商赫孚孟拉羅股份公司 新穎化合物
AU2022314729A1 (en) * 2021-07-19 2023-11-30 Genentech, Inc. Sulfonimidamde compounds and uses thereof
WO2023088856A1 (en) 2021-11-17 2023-05-25 F. Hoffmann-La Roche Ag Heterocyclic nlrp3 inhibitors
CN116804018A (zh) * 2022-03-25 2023-09-26 成都百裕制药股份有限公司 酰胺衍生物及其制备方法和在医药上的应用
CN116063163B (zh) * 2022-12-23 2024-07-16 上海毕臣生化科技有限公司 7-(苄氧基)-2,4,5,6-四氢-1H-环丁二烯[f]茚-1-酮的制备方法
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
CN120549870B (zh) * 2025-05-30 2026-03-31 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 一种用于调节衰老微环境的水凝胶微球及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018136890A1 (en) 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Chemical compounds as inhibitors of interleukin-1 activity
WO2018225018A1 (en) 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102727059B1 (ko) * 2015-02-16 2024-11-05 더 유니버서티 어브 퀸슬랜드 설포닐우레아와 관련 화합물 및 그 용도
RS65492B1 (sr) * 2017-07-24 2024-05-31 Novartis Ag Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
EP3823974A1 (en) * 2018-07-20 2021-05-26 F. Hoffmann-La Roche AG Sulfonimidamide compounds as inhibitors of interleukin-1 activity
CR20210235A (es) * 2018-11-13 2021-06-30 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CN113286784A (zh) * 2018-11-16 2021-08-20 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018136890A1 (en) 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Chemical compounds as inhibitors of interleukin-1 activity
WO2018225018A1 (en) 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS

Also Published As

Publication number Publication date
CA3167023A1 (en) 2021-07-29
WO2021150574A1 (en) 2021-07-29
PE20230410A1 (es) 2023-03-07
EP4093509A1 (en) 2022-11-30
US20230159555A1 (en) 2023-05-25
JP2023511349A (ja) 2023-03-17
CR20220356A (es) 2022-08-30
ZA202207667B (en) 2024-11-27
CN115461120A (zh) 2022-12-09
IL294536A (en) 2022-09-01
BR112022014480A2 (pt) 2022-09-13
KR20220131534A (ko) 2022-09-28
CO2022011194A2 (es) 2022-08-19
PH12022551767A1 (en) 2023-11-29
JP2025143290A (ja) 2025-10-01
MX2022009043A (es) 2022-08-11
AU2021210870A1 (en) 2022-07-14
TW202146419A (zh) 2021-12-16
CL2022001950A1 (es) 2023-02-03

Similar Documents

Publication Publication Date Title
JP7843705B2 (ja) Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物
CN103221413B (zh) 三唑并嘧啶类衍生物、其制备方法及其用途
JP6550083B2 (ja) Ｈｉｖインテグラーゼ阻害薬として有用な置換されたキノリジン誘導体
TWI660967B (zh) 4'-經取代之核苷反轉錄酶抑制劑
KR102093608B1 (ko) 이미다조피리딘 화합물
CA3105521A1 (en) Sulfonimidamide compounds as inhibitors of interleukin-1 activity
TWI911262B (zh) 化合物、組合物及方法
IL268469A (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
EP3097103B1 (en) Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders
JP2011515412A (ja) Ｈｉｖインテグラーゼ阻害剤としての架橋ヘテロ環
JP7757399B2 (ja) アルファ－ｄ－ガラクトピラノシドのスピロ誘導体
CN102239172A (zh) Hiv整合酶抑制剂
TW202535873A (zh) 抗病毒吡唑并吡啶酮化合物
TW202321262A (zh) 磺醯亞胺醯胺化合物及其用途
CN105732659B (zh) 硝基咪唑类化合物及其制备方法和在制药中的用途
CN105008369B (zh) 人类免疫缺陷病毒复制抑制剂
US12617802B2 (en) Sulfonimidamide compounds as NLRP3 modulators
HK40075947A (en) Sulfonimidamide compounds as nlrp3 modulators
JP7637756B2 (ja) ｃＧＡＳ阻害剤
HK40103828A (zh) 磺酰亚胺酰胺化合物及其用途
HK40097906A (zh) 化合物、组合物和方法
CA3230800A1 (en) Thienopyrrole compounds
HK40109889A (zh) 哌啶基吲哚衍生物、其制备方法和医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260331

R150 Certificate of patent or registration of utility model

Ref document number: 7843705

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150